[ad_1]
Three doses of the Pfizer vaccine against Covid 19 offer strong protection for children under the age of 5, the Pfizer company announced on Monday.
The firm plans to provide the data to U.S. regulators later this week, the first step toward approving the vaccine for children under the age of five.
The news comes after months of anxious waiting from parents wanting to vaccinate their children under 5, especially now that there is an increase in cases with Covid 19. 18 million children under 5 are the only group in the United States who do not qualify get the vaccine against Covid 19.
The Food and Drug Administration (FDA) has begun evaluating the data from rival company Moderna, which hopes to start offering a two-dose vaccine to children this summer.
Pfizer has had a harder time in this regard. She tried to give young children a lower dose than one-tenth the dose for adults, but clinical trial found that two doses did not provide enough protection for children under 5 years of age. Therefore, the researchers gave a third dose to more than 1,600 children aged 6 months to 4 years, during the winter when there was an increase in cases with the “Omicron” variant of the coronavirus.
In a press release, Pfizer and its partner BioNTech said the extra dose provided stronger protection, raising antibody levels of the virus in children under the age of 5, enough to meet the Food and Drug Administration’s criteria for emergency use of the vaccine without safety problems.
top channel
[ad_2]
Source link
